COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.
New data shows the drug is not more likely to cause birth defects.
March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.
Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.